bination, as well as a breakdown in the fidelity of chromosome segregation during mitosis and meiosis (Gangloff et al., 1994; Watt et al., 1995 Watt et al., , 1996 . In addition, interspecies cross-functionality between BLM and SGS1 has been indicated by the observation that BLM is capable of partially suppressing the hyper-recombination phenotype of sgs1 mutants and restoring the slow growth phenotype of a top3 sgs1 double mutant (Yamagata et al., 1998) . Further evidence for a role of BLM in HR comes from the observation that BLM directly interacts with RAD51, and co-localises with it in the nucleus of cells exposed to DNA damaging agents (Bischof et al., 2001; Wu et al., 2001) . Furthermore, the enzymatic activity of the BLM helicase is also consistent with a role in HR: BLM can disrupt synthetic D-loop structures and catalyse branch migration of Holliday junctions (HJ) and synthetic four-way junctions van Brabant et al., 2000; Mohaghegh et al., 2001) , which arise as intermediates during HR, and may occur spontaneously during DNA replication and repair . BLM has recently been shown to interact with p53 (Garkavtsev et al., 2001; Wang et al., 2001) . This interaction attenuates the ability of BLM to unwind synthetic HJ in vitro (Yang et al., 2002) and is necessary to transport p53 to sites of stalled DNA replication forks where the two proteins functionally interact to modulate HR (Sengupta et al., 2003) . Moreover, the presence of BLM in the two multiprotein complexes BASC (BRCA1-Associated genome Surveillance Complex), together with hMSH2, hMSH6, hMLH1, ATM, the RAD50-MRE11-NBS1 complex and replication factor C (Wang et al., 2000) , and BRAFT, containing also five Fanconi anemia complementation group proteins, topoisomerase IIIα and replication protein A (Meetei et al., 2003) , suggests a functional link to DNA repair.
The DNA mismatch repair (MMR) system is a conserved pathway involved in the removal of mispaired bases from DNA, which plays an important role in the maintenance of genomic stability in both prokaryotes and eukaryotes (reviewed in Bellacosa, 2001) . The E. coli MutHLS MMR pathway has been well characterised biochemically and genetically (Modrich and Lahue, 1996) , and has served as a paradigm for the yeast and mammalian MMR pathways. A number of homologues of MutS and MutL MMR proteins have been described in yeast and mammalian cells. Base/base mismatches and small insertion/deletion loops are recognised by the hMutSα complex, which is a heterodimer of hMSH2 and hMSH6. hMSH2 also pairs with another MutS homologue, hMSH3, to form a heterodimer known as hMutSß, which is involved in the repair of larger insertion/deletion loops. Following this initial mismatch-recognition step, homologues of the bacterial MutL ATPase, predominantly the hMLH1-hPMS2 (hMutLα) heterodimer in humans, couple mismatch recognition to the appropriate downstream processing steps. Interestingly, defects in some of the MMR proteins lead to an inherited cancer syndrome called hereditary non-polyposis colon cancer (HNPCC). Mutations in two MMR genes, hMSH2 and hMLH1, have typically been associated with HNPCC, while mutations in other MMR genes (hMSH6, hPMS1, and hPMS2) are rare.
In addition to their role in the repair of replication errors, MMR proteins have been implicated in some aspects of HR (reviewed in Evans and Alani, 2000; Bellacosa, 2001 ). In mammalian cells, as in other organisms, HR is well established as one of the major pathways for the repair of DNA double-strand breaks. MMR components have been shown to function in HR by suppressing recombination between homeologous sequences (similar, but not identical), a role that appears to be conserved in bacteria, yeast, and mammals (Modrich and Lahue, 1996) . The hMutSα complex has also been shown to bind to HJs, suggesting that it may be involved in additional HR processes in vivo (Marsischky et al., 1999) . Moreover, hMSH2 -/-and hMSH6 -/-murine embyonic stem cells are promiscuous during recombination between homologous sequences in gene-targeting experiments (de Wind et al., 1995 (de Wind et al., , 1999 .
We and others have recently demonstrated that BLM interacts directly with the MMR protein hMLH1 (Langland et al., 2001; Pedrazzi et al., 2001) . Since BS cells are not deficient in MMR, it has been proposed that the hMLH1 interaction with BLM may play a role in HR (Langland et al., 2001; Pedrazzi et al., 2001) . In this study, we set out to test whether BLM interacts also with other components of the MMR system. We demonstrate here that BLM interacts directly with hMSH6, but not with the hMSH2 component of the MutSα heterodimer. Consistent with this notion is the observation that BLM and hMSH6 co-immunoprecipitate from human nuclear extracts and co-localise to nuclear foci in response to ionising radiation. Taken together, our data provide further evidence for a role of BLM helicase alongside MMR proteins in HR.
Results

BLM Directly Interacts with hMSH6 But Not with hMSH2
To examine whether BLM interacts with components of the MMR system in addition to hMLH1, we performed a dot-blot assay where we immobilised increasing amounts of purified recombinant MutSα (Iaccarino et al., 1998) , MutLα (positive control) (Raschle et al., 1999) , or phage protein D (negative control), onto a nitrocellulose membrane, and incubated the membrane with purified recombinant BLM protein (Karow et al., 1997) . The presence of bound BLM protein was detected using an antibody against BLM. As shown in Figure 1A , BLM interacts with the MutSα heterodimer, although to a slightly lesser extent than with the MutLα complex. Knowing that BLM directly interacts with at least one of the components of MutSα complex, we sought to identify whether this inter-action was with hMSH2 and/or hMSH6. For this, we performed a Far-Western blot analysis. Figure 1B shows a Coomassie Blue stained gel with the purified recombinant proteins. MutSα was separated into its two components, hMSH2 and hMSH6, by SDS-PAGE and the proteins were then renatured on the membrane after blotting. Subsequently, lanes 2 to 4 ( Figure 1C ) of the membrane were probed with purified recombinant BLM protein. Western analysis with an anti-BLM antibody (IHIC33) revealed bands at the positions corresponding to hMHS6 (lane 4) and the positive control hMLH1 (lane 2) after incubation with BLM as well as for the BLM input (lane 7). No signal was detected at the positions of the negative controls hPMS2 (lane 2) and BSA (lane3) nor at the position of the hMSH2 protein (lane4). Cross-reactivity of the anti BLM antibody with hMSH6 can be excluded, as it did not recognize the protein that had not been incubated with BLM (lane 6). The amount of BLM bound to hMSH6 strongly increased when MutLα complex was added to the reaction (data not shown), although the mechanism underlying this effect is not known and awaits further investigation.
BLM and hMHS6 Form a Complex in Human Cells
To confirm the BLM/hMSH6 interaction detected by the Far-Western assay, and to assess whether this interaction can be detected in human cells, we performed coimmunoprecipitation experiments on nuclear extracts from HeLa cells. Using a monoclonal antibody against hMSH6, we were able to specifically co-immunoprecipitate BLM (Figure 2A , lane 3). No BLM was present in the precipitate when a control antibody was used ( Figure 2A , lane 2). Similarly, BLM could not be co-immunoprecipitated with an anti-hMSH6 antibody from hMSH6-deficient HCT15 nuclear extracts ( Figure 2A , lane 5). Reciprocal co-immunoprecipitation experiments showed that hMSH6 could specifically be precipitated with a poly-BLM Interaction with hMSH6 1157 (lane 7) were separated by SDS-PAGE and blotted onto a nitrocellulose membrane. After renaturation, lanes 2 to 4 of the membrane were incubated with purified recombinant BLM (1 µg/ml) and the presence of bound BLM protein was detected by Western analysis using an anti-BLM antibody. Lane 1 was probed with an antibody against hMLH1, lane 5 with antibodies against hMSH2 and hMSH6 and lanes 6 and 7 were probed with an anti-BLM antibody. clonal anti-BLM antibody ( Figure 2B , lane 3) from HeLa nuclear extracts. We observed no increase in the amount of co-immunoprecipitated BLM/hMSH6 complex upon the addition of native DNA or mismatched DNA (data not shown).
Mapping of BLM and hMSH6 Interaction Regions
To investigate the region of BLM protein that is responsible for mediating the interaction with hMSH6, different BLM deletion mutants were transcribed and translated in vitro (IVTT) and used as radioactive probes to test for their ability to interact with full-length hMSH6 in an in vitro binding assay (IBA). As described above, the recombinant MutSα complex was separated by SDS-PAGE and its constituent polypetides were renatured on the membrane after blotting. As a negative control, BSA was included on the membrane. Where possible, based on previous mapping data, the translated BLM fragments were tested for their binding to hMLH1, in order to confirm the correct folding of the IVTT BLM fragments. As shown in Figure 3A , the result of the IBA revealed two separate regions on BLM that are required for binding to hMSH6. While no interaction could be observed with the N-terminal BLM-construct (amino acids 1 -448), both an internal fragment covering amino acids 340 -770, and a C-terminal fragment spanning amino acids 904 -1417 showed binding to hMSH6. Neither of these fragments bound to BSA or hMSH2. We conclude that BLM contains two separate hMSH6-binding regions. (A) Two separate regions on BLM interact with hMSH6. Recombinant MutSα complex (1µg), MutLα (1 µg) and BSA (1 µg) were separated by SDS-PAGE and blotted onto a nitrocellulose membrane. After renaturation, the membranes were incubated with [ 35 S]-labelled IVTT BLM fragments. Black bars show fragments that were able to bind to hMSH6, but not to hMSH2 or BSA, white bars represent fragments that do not bind to hMSH6. The Table summarises the obtained results with all tested proteins (+: interaction; -: no interaction; nd: not determined). The sketch of BLM shows the position of the helicase domain (vertically striped, amino acids 649 -1005), the HRDC domain (horizontally striped, amino acids 1212 -1292) and the nuclear localisation signals (black bar, amino acids 1334 -1349). The grey bars below depict the regions mediating the interaction with hMLH1. (B) hMSH6 interacts with BLM via two distinct regions. Aliquots of 0, 0.25 and 0.5 µg of purified recombinant BLM protein or MutSα complex (positive control), or 0, 0.5 and 1 µg of BSA (negative control) were spotted onto a nitrocellulose membrane and probed with the indicated IVTT fragments. Black bars represent positive interactions, white bars non-interacting fragments. An overview of all tested interactions is shown in the Table (+: interaction, -: no interaction). The sketch shows the regions of hMSH6 interacting with PCNA (black, amino acids 3 -22) and hMSH2 (dark grey, amino acids 326 -575 and 1302 -1360) as well as the residue important for mismatch binding (light grey, amino acid 432). *As full-length IVTT hMSH6 was highly prone to degradation, it was co-produced with hMSH2.
To identify which regions of hMSH6 are involved in binding to BLM, we used a similar approach, in which increasing amounts of purified recombinant BLM protein (and MutSα as a positive control and BSA as a negative control) were dotted onto a nitrocellulose membrane, and probed with [ 35 S]-labelled IVTT deletion mutants of hMSH6, or IVTT full-length hMSH6. Due to rapid degradation when produced alone, hMSH6 was co-translated with hMSH2. hMSH2 alone did not interact with BLM (data not shown). Fragments represented by black bars show positive interactions, while white bars show constructs not interacting with BLM ( Figure 3B ). We conclude therefore, that two BLM-interacting regions are present on hMSH6, one in the N-terminal half (amino acids 1 -718) and one at the very C-terminus (amino acids 1000 -1360). A more detailed mapping of the Nterminal fragment was not successful as a fragment covering amino acids 1 -305 was not able to bind to a positive control (hMSH6-interacting protein), PCNA, possibly due to misfolding, and therefore we were unable to draw any conclusions about a potential interaction with BLM.
BLM and hMSH6 Co-Localise to Discrete Nuclear Foci in Response to Ionising Radiation
The co-immunoprecipitation of BLM and hMSH6 from human nuclear extracts, as well as the evidence for a direct interaction between purified BLM and hMSH6, is consistent with these proteins forming a complex in vivo and in vitro. To provide additional evidence for this, we asked whether BLM and hMSH6 co-localise within the nucleus of human cells. Previous studies in HeLa and WI-38/VA-13 human cells have shown that BLM localises to nuclear foci corresponding to PML nuclear bodies (Ishov et al., 1999; Sanz et al., 2000; Yankiwski et al., 2000; Bischof et al., 2001; Wu et al., 2001) , as well as to the nucleolus during certain stages of the cell cycle (Yankiwski et al., 2000) . However, BLM has also been shown to colocalise with sites of ongoing DNA replication, at least in a subset of late S-phase cells (Wu et al., 2000a) . Immunofluorescence studies conducted with MMR-proficient HeLa cells showed that, in cells undergoing DNA replication, hMSH6 co-localises with PCNA to nuclear foci, which most likely represent replication complexes (Kleczkowska et al., 2001) . In untreated WI38/VA-13 cells, we found only very rare cases where BLM-containing nuclear foci appeared to co-localise with hMSH6 ( Figure 4, upper panel) . We therefore asked if the number of co-localising BLM/hMSH6 foci might increase in response to DNA damage. One hour after 10 Gy of γ-irradiation, the proportion of cells containing BLM and hMSH6 co-localising foci increased, although co-localisation (at least to discrete foci) was still a rare event (Figure 4 , lower panel).
The MutS␣ Complex Does Not Appear to Influence the DNA Helicase Activity of BLM
The observation that BLM and hMSH6 interact directly and can co-localise in nuclear foci following exposure of cells to ionising radiation indicate that the two proteins may be involved in a common cellular pathway. Since the helicase activity of BLM is necessary for the promotion of Holliday junction (HJ) branch migration Yang et al., 2002) , we investigated whether purified recombinant MutSα complex might modulate the ability of BLM to disrupt a radiolabeled synthetic X-junction substrate, a mimic of the HJ ( Figure 5A ). Consistent with previous reports Yang et al., 2002) , the purified recombinant BLM disrupted the X-junction in a dose-dependent manner into primarily two-armed products (the product of branch migration) as well as some one-armed (single-stranded DNA) product generated by the unwinding of the 2-armed species ( Figure lanes 3 -9). In the absence of BLM, purified recombinant MutSα complex did not show any intrinsic helicase activity ( Figure 5A, lane 18) . To test the effect of MutSα on the ability of BLM to disrupt the X-junction, increasing amounts of BLM (8 -25 fmol) were incubated with the Xjunction in the presence of a molar excess of purified recombinant MutSα complex (200 fmol). No effect of Mut-Sα on the DNA helicase activity of BLM was observed under these conditions ( Figure 5A, chart) , or when increasing amounts of purified recombinant MutSα complex (6.25 -400 fmol) were used in reactions where the amount of BLM was kept at a fixed level (11.25 fmol; data not shown).
We next asked if MutSα might influence BLM helicase activity on a different DNA substrate. To that end, a forked DNA structure that mimics a simplified version of a replication fork was incubated with increasing amounts of BLM (8 -25 fmol) and a fixed amount of MutSα complex (200 fmol). As shown in Figure 5B (chart), MutSα did not stimulate or inhibit BLM unwinding of a forked DNA structure.
Discussion
The molecular roles of the BLM gene product in the maintenance of genomic stability in human cells still remain to be defined. In the present study, we have shown that the Bloom's syndrome helicase interacts in vivo and in vitro with hMSH6, a protein involved in MMR. Hence, BLM makes physical interactions with components (hMSH6 and hMLH1) of the two major MMR heterodimeric complexes, MutSα and MutLα. We have demonstrated that BLM interacts directly with hMSH6 via two separate sites comprising the amino acids 340 -770 and 904 -1417 of BLM. In addition, we have shown that two regions of hMSH6 (amino acids 1 -718 and 1000 -1360) mediate the interaction with BLM. However, immunofluorescence data suggest that BLM and hMSH6 may only co-localise to a limited extent in response to DNA damage. Further work is required to identify whether co-localisation occurs more dramatically in cells exposed to stresses other than γ-irradiation.
Various experiments performed in the past three years have suggested a likely role for BLM in HR repair through its ability to disrupt synthetic D-loop substrates and/or to promote the ATP-dependent translocation of HJ van Brabant et al., 2000; Mohaghegh et al., 2001; Yang et al., 2002) , a function that may suppress inappropriate DNA recombination in vivo. Consistent with these observations, BLM has been shown to interact with RPA (Brosh et al., 2000) , RAD51 (Wu et al., 2001) , hMLH1 (Langland et al., 2001; Pedrazzi et al., 2001) , and p53 (Wang et al., 2001) , four proteins known also to influence HR repair. In the case of the BLM/p53 interaction, Yang et al. have demonstrated recently that purified recombinant p53 attenuates the ability of BLM to unwind synthetic HJs in vitro (Yang et al., 2002) . Thus, a role for BLM as an 'anti-recombinase' in the suppression of genome instability is now suggested. Nevertheless, why should it be necessary for BLM to interact with mismatch repair proteins such as hMSH6 and hMLH1 during this or related HR processes? We suggest that the most likely answer to this question lies in the property of at least some MMR proteins to participate in HR in addition to their role in the post-replicative mismatch repair (reviewed in Bellacosa, 2001 ). MMR proteins have been shown to be antirecombinogenic in yeast and bacteria, to be involved in regulation of heteroduplex length in yeast and mice, and to suppress homeologous recombination (reviewed in Modrich and Lahue, 1996; Evans and Alani, 2000; Harfe and Jinks-Robertson, 2000) . In addition to these observations, the MutSα complex can bind with high affinity and specificity to HJ (Marsischky et al., 1999) , and thus may be involved in the HR repair process in vivo by rendering the HJ more accessible to other processing components. These data, combined with evidence that BLM serves to prevent inappropriate HR during DNA replication, lead us to propose that MMR proteins such as hMSH6 and hMLH1 may assist BLM to perform its 'antirecombinase' function by modulating its branch migration activity leading to the restoration of a functional replication fork structure. In this way, MMR proteins could serve as 'docking sites' to position BLM at sites of HR repair. However, we could not observe any effect of the purified recombinant MutSα complex on the ability of BLM to unwind synthetic HJ in our in vitro helicase experiments. Nevertheless, it seems unlikely that BLM and MutSα act alone and therefore any modulation of BLM activity, if it occurs, may require one or more additional components of the MMR or HR machinery.
Clearly, the physical interactions that exist between BLM and hMSH6, and between BLM and hMLH1 (Langland et al., 2001; Pedrazzi et al., 2001) , strongly suggest that BLM is intimately linked to some aspect(s) of the MMR process. Given that Bloom's syndrome cells are MMR proficient, BLM is unlikely to function in 'generalised' MMR, but is more likely involved in the regulation of genetic recombination. Further establishing these links by more sophisticated functional assays is a critical next step in the investigation of the functional connections between BLM and MMR proteins during HR. It will also be interesting to determine whether WRN and RECQL4, other members of the RecQ family helicases that are defective in Werner's and Rothmund-Thomson syndromes, respectively, also interact physically and functionally with the MMR proteins. These studies will certainly lead to a deeper understanding of the fundamental roles of the MMR proteins and RecQ helicases in DNA replication and HR repair.
Materials and Methods
Hela Nuclear Extracts
Extracts were prepared as described in Perkins et al. (1994) .
Construction of Plasmids
The different hMSH6 plasmids for in vitro transcription were generated by PCR using the hMSH6 cDNA as a template, followed by cloning into vectors of the pCite-4 series (Novagen, Madison, USA). For constructs used in interaction site mapping on BLM, see Pedrazzi et al. (2001) . Sequences of all plasmids and construction schemes are available upon request.
Co-Immunoprecipitation Experiments
Two-hundred µg of Hela cell nuclear extracts were incubated for one hour at 4°C in 1× binding buffer (20 mM Tris/HCl pH 7.5, 5 mM MgCl 2 , 1 mM PMSF, 1 mM glutathione, 0.1 mM dNTPs, 50 µg/ml BSA), supplemented with 10% sucrose and 1× protease inhibitor cocktail, EDTA-free (Roche, Basel, Switzerland) and 0.05 µg/ml polydIdC (Fluka, Buchs, Switzerland) with an effective salt concentration of 80 mM NaCl. Two µg of the mouse monoclonal anti-hMSH6 antibody (MCA 1687; Serotec, Oxford, UK) or a mouse IgG control antibody for the hMSH6 were used in the immunoprecipitation experiments. Alternatively, 4 µg of the polyclonal goat anti-BLM antibody C-18 (Santa Cruz, Santa Cruz, USA) or a goat IgG control antibody were used in BLM immunoprecipitations. In each case, the incubations were continued for two hours. Twenty µl of protein G Dynabeads (Dynal, Hamburg, Germany) were added to the solution and the incubation was continued for a further 1.5 h before the matrix-bead proteins were isolated according to the instructions of the manufacturer. The beads were washed five times with 200 µl of binding buffer (100 mM NaCl for IP with antihMSH6 antibody, and 100 mM NaCl plus 150 mM KCl for anti-BLM antibody) before elution with 2× Laemmli buffer. The immunoprecipitated proteins were subjected to Western blot analysis using a polyclonal anti-hMSH6 antibody (Palombo et al., 1995) or the polyclonal anti-BLM IHIC33 antibody (Wu et al., 2000b) . Detection was performed using ECL (Amersham Pharmacia Biotech, Uppsala, Sweden) following the manufacturer's instructions.
Far-Western Analysis
This assay was performed essentially as described previously (Wu et al., 2000b) . Briefly, 1 µg of purified hMutSα, 1 µg of BSA and 0.5 µg of purified hMutLα were subjected to SDS-PAGE and transferred to nitrocellulose filters. After renaturation and blocking, the filters were incubated for 60 min in a solution containing BLM (1 µg/ml) in TBS supplemented with 0.25% milk, 0.3% Tween 20, 1 mM DTT and 1 mM PMSF. After extensive washing, conventional Western blotting was performed to detect the presence of BLM (antibody IHIC33). The inputs were visualised with antibodies against hMLH1 (G168-15; Pharmingen, San Diego, USA), hMSH2 (Ab-2; Calbiochem, San Diego, USA), hMSH6 (21F10, Serotec) and BLM (IHIC33). For Figure 1A , MutSα, MutLα and protein D were directly spotted onto the membrane in increasing amounts (0, 0.4, 0.8, 1.6, 3.2 and 6.4 pmoles) and incubated with BLM (3 µg/ml) as described below for the in vitro binding assay. Detection of bound BLM protein was as outlined above.
In Vitro Binding Assay
Different amounts of recombinant BLM and BSA were directly spotted onto a nitrocellulose membrane (Micron Separation Inc., Westborough, USA), while hMutSα was subjected to SDS-PAGE prior to transfer to the nitrocellulose membrane followed by renaturation/denaturation steps as described for the Far Western assay. After blocking for one hour at room temperature using TBS supplemented with 5% non-fat milk and 0.5% Tween, the membrane was incubated for three hours at 4°C with different proteins that were [ 35 S]-labelled using the TNT T7 quick-coupled transcription/translation system (Promega, Mannheim, Germany) in 1 ml TBS with 0.5% Tween and 0.1% BSA. Fifty µl (of BLM fragments and full-length hMSH6-hMSH2 complex) or 75 µl (hMSH6 fragments) of the in vitro transcription and translation reactions were used for each incubation. After extensive washing with TBS supplemented with 0.5% Tween, the membranes were dried and exposed to a PhosphorImager (Molecular Dynamics, Sunnyvale, USA).
Indirect Immunofluorescence Analysis
Indirect Immunofluorescence Analysis was performed essentially as described in Wu et al. (2000b) , with slight modifications. Cells were grown on coverslips and fixed with 4% paraformaldehyde, 250 mM HEPES, pH 7.4 at 4°C for 20 min, and then permeabilised in 0.1% Triton X-100 in PBSA for 20 min. After washing 5 times in PBSA for 20 min, blocking was carried out at 37°C for 20 min in 10% foetal bovine serum, 0.1% Triton X-100 in PBSA. The coverslips were incubated for 1 h at 37°C with the primary antibodies IHIC33, or hMSH6/GTBP (BD Transduction Laboratories, Lexington, USA), which were diluted in the above blocking solution at 1:200, and 1:800, respectively. Five washes in PBSA for 20 min were followed by incubation with anti-mouse Cy3 (Sigma, St. Louis, USA), anti-rabbit fluorescein isothiocyanate (Dako, Glostrup, Denmark) or anti-rabbit AlexaFluor 488 (Molecular Probes, Eugene, USA) secondary antibodies for 1 hour at 37°C at 1/800, 1/200 and 1/800 dilutions, respectively. Cells were washed five times in PBSA, and the DNA was stained using Hoechst 33258 at 50 ng/ml. Stained slides were mounted in 90% glycerol, 20 mM Tris-HCl, pH 8.0, and 50 µg/ml paraphenylenediamine. Slides were viewed at 100× magnification on a Zeiss Axioskop microscope. Image acquisition and analysis were performed using the AxioVision (Zeiss, Jena, Germany) software, and the images were merged using Adobe Photoshop.
DNA Helicase Assays
Approximately 0.075 fmol of oligonucleotide-based 4-way junction or forked duplex substrate (Mohaghegh et al., 2001) were incubated with the indicated amounts of BLM and hMutSα proteins in a 10 µl reaction volume at 37°C for 45 minutes in helicase buffer (33 mM Tris-acetate pH 7.8, 1 mM Mg-acetate, 66 mM K-acetate, 0.1 mg/ml BSA, 1 mM DTT, 1 mM ATP). The reaction was stopped by the addition of 1/10 volume loading buffer (100 mM Tris-HCl, 100 mM EDTA, bromophenol blue and xylene cyanol). The samples were electrophoresed on 10% acrylamide gels in 1× TBE at 25 mA for 1 h at 4°C. The gels were dried at 80°C for 30 min and subjected to autoradiography. Quantitative analysis of the rate of unwinding was performed on a Storm 840 PhosphorImager and ImageQuant software (Molecular Dynamics).
